Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

被引：3
|
作者：
Allen, Pamela [1 ]
Chen, Qing C. [2 ]
Lu, Xinyan [2 ]
O'Shea, Kaitlyn [3 ]
Chmiel, Joan [4 ]
Sukhanova, Madina [2 ]
Slonim, Liron Barnea [2 ]
Savas, Hatice [5 ]
Mou, Eric [6 ]
Pro, Barbara [7 ]
Evens, Andrew M. [8 ]
Palmer, Brett Alan [7 ]
Advani, Ranjana [9 ]
Gordon, Leo I. [7 ]
Winter, Jane N. [7 ]
机构：
[1] Emory Univ, Winship Canc Inst, Decatur, GA USA
[2] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[4] Northwestern Univ, Dept Biostat, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Radiol, Chicago, IL 60611 USA
[6] Stanford Univ, Dept Med, Div Oncol, Palo Alto, CA USA
[7] Northwestern Univ, Div Hematol & Oncol, Chicago, IL 60611 USA
[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[9] Stanford Canc Inst, Saul A Rosenberg Prof Lymphoma, Dept Med, Div Oncol, Stanford, CA USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147042
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
231
引用
收藏
页数：4
相关论文
共 44 条
  • [1] Frontline Treatment With Single- Agent Pembrolizumab Followed by AVD Chemotherapy for Classical Hodgkin Lymphoma: Updated Results and Correlative Analysis
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 3 - 4
  • [2] Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy
    Allen, Pamela B.
    Bazzi, Latifa
    Zhang, Bin
    Chen, Qing
    Slonim, Liron Barnea
    Savas, Hatice
    Advani, Ranjana H.
    Evens, Andrew M.
    Pro, Barbara
    Karmali, Reem
    Mou, Eric
    Eisner, Robert
    Bayer, Robert
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2024, 144 : 1664 - 1665
  • [3] PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy
    Allen, Pamela B.
    Lu, Xinyan
    Chen, Qing C.
    Slonim, Liron Barnea
    Sukhanova, Madina
    Savas, Hatice
    Chmiel, Joan
    O'Shea, Kaitlyn
    Evens, Andrew M.
    Advani, Ranjana
    Pro, Barbara
    Karmali, Reem
    Palmer, Brett Alan
    Bearden, Jeffrey
    Mou, Eric
    Dillehay, Gary
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2020, 136
  • [4] Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab plus AVD for Classic Hodgkin Lymphoma
    Kuczmarski, Thomas M.
    Ujjani, Chaitra S.
    Poh, Christina
    Warren, Edus H.
    Smith, Stephen D.
    Shadman, Mazyar
    Till, Brian G.
    Raghunathan, Vikram
    Tseng, Yolanda
    Du, Hongyan
    Vandermeer, Jacquelin
    Kelly, Alyssa
    Rasmussen, Heather
    Voutsinas, Jenna M.
    Gopal, Ajay K.
    Lynch, Ryan C.
    BLOOD, 2024, 144 : 1667 - 1668
  • [5] Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant
    Steiner, Raphael Eric
    Becnel, Melody R.
    Cuglievan, Branko
    Nair, Ranjit
    Singh, Prachee
    Strati, Paolo
    Jain, Preetesh
    Ahmed, Sairah
    Samaniego, Felipe
    Gunther, Jillian R.
    Pinnix, Chelsea C.
    Fang, Penny
    Dabaja, Bouthaina S.
    Feng, Lei
    Lee, Hun Ju
    BLOOD, 2020, 136
  • [6] Brentuximab Vedotin and AVD Chemotherapy Followed by ISRT: A Safe Primary Treatment Regimen for Early-Stage, Unfavorable Hodgkin Lymphoma
    Yang, J. C.
    Kumar, A.
    Chapman, K. L.
    Constine, L. S.
    Moskowitz, C. H.
    Yahalom, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S21 - S21
  • [7] Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial
    Bryan, Locke J.
    Casulo, Carla
    Allen, Pamela
    Smith, Scott E.
    Savas, Hatice
    Karmali, Reem
    Pro, Barbara
    O'Shea, Kaitlyn
    Chmiel, Joan
    Palmer, Brett Alan
    Mehta, Jayesh
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2021, 138
  • [8] Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD
    Allen, Pamela
    Savas, Hatice
    Evens, Andrew M.
    Pro, Barbara
    Karmali, Reem
    Palmer, Brett Alan
    Mou, Eric
    Bearden, Jeffrey
    Scholtens, Denise M.
    Dillehay, Gary
    Gordon, Leo I.
    Winter, Jane N.
    BLOOD, 2019, 134
  • [9] METHOTREXATE AS A SINGLE AGENT AND IN COMBINATION CHEMOTHERAPY FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA OF UNFAVORABLE HISTOLOGY
    CANELLOS, GP
    SKARIN, AT
    ROSENTHAL, DS
    MOLONEY, WC
    FREI, E
    CANCER TREATMENT REPORTS, 1981, 65 : 125 - 129
  • [10] Brief Pembrolizumab Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients With Classical Hodgkin Lymphoma: A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 14 - 15
12345